GeneDx Holdings (WGS), Why Is This Fresh Development Drawing Attention?
GeneDx Holdings (WGS) has launched an online exome testing pathway, allowing U.S. families to directly initiate clinician-guided genetic tests for children with developmental conditions. This development comes as the stock shows strong recent momentum, despite significant year-to-date and one-year declines. While one valuation model suggests the stock is slightly overvalued, another (Simply Wall St's DCF) indicates deep undervaluation, highlighting mixed sentiment and the importance of examining underlying data.
WGS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026
Faruqi & Faruqi, LLP is investigating potential claims against GeneDx Holdings Corp. (NASDAQ: WGS) and reminds investors of the August 3, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that GeneDx and its executives made false and misleading statements regarding the importance of Fabric Genomics, the durability of reimbursement rates, and the company's gross margins. This follows a significant drop in share price after GeneDx disclosed missed Q1 financial results and cut 2026 guidance, revealing a goodwill impairment charge related to the Fabric Genomics acquisition.
GeneDx Holdings Corp. (NASDAQ:WGS) Analysts Are Pretty Bullish On The Stock After Recent Results
Analysts are showing increased optimism for GeneDx Holdings Corp. (NASDAQ:WGS) after its latest second-quarter results, which saw revenues beat expectations and statutory losses narrow more than anticipated. Although revenue forecasts remain unchanged for the coming year, analysts have revised their loss per share predictions, leading to a 5.0% increase in the consensus price target to US$85.89. The company's revenue growth is projected to outpace the industry average, despite a slowdown compared to its historical performance.
GeneDx (WGS) Stock Climbs On Strong Margins As Reimbursement Lags
GeneDx Holdings Corp. (WGS) saw its stock climb 4.8% after reporting strong Q2 2026 results, with exome and genome revenue reaching US$100.3 million and a gross margin of around 70%. The company achieved adjusted profitability ahead of schedule, demonstrating its core engine's efficiency. However, reimbursement challenges persist, with blended average reimbursement per test remaining flat and outpatient genome collection below industry targets, raising concerns about the durability of its profit profile.
[10-Q] GeneDx Holdings Corp. Quarterly Earnings Report
GeneDx Holdings Corp. (WGS) filed its quarterly earnings report (Form 10-Q) for the period ended June 30, 2026. The report details a new financing structure involving an amended loan agreement for an additional $50 million, increasing debt capacity to $150 million, and a conditional share issuance of approximately $5 million to Blackstone affiliates, which could dilute existing shareholders. The company reported a net loss of $17.7 million for Q2 2026 and $81.1 million for the six months ended June 30, 2026, and also recorded a $31.3 million impairment loss related to the Fabric Genomics acquisition.
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026
Faruqi & Faruqi, LLP reminds investors of the August 3, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS). The lawsuit alleges that GeneDx and its executives made false and misleading statements regarding the importance of Fabric Genomics, its margins, and reimbursement rates, leading to significant stock price drops. Investors who purchased WGS stock between April 16, 2025, and May 4, 2026, and suffered losses are encouraged to contact the law firm.
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) is reminding investors of a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) for alleged securities fraud. The lawsuit claims GeneDx made misleading statements, revealed a drop in adjusted gross margin, lowered projected earnings, and announced a significant impairment, causing investor damages. Shareholders who purchased WGS shares during the class period (April 16, 2025, to May 4, 2026) are encouraged to contact SBS to discuss potential lead plaintiff appointments before the August 3, 2026 deadline.
Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of investors who purchased securities between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made materially false and misleading statements regarding the importance of Fabric Genomics, its declining margins, and non-durable reimbursement rates. Investors who suffered losses are encouraged to contact the firm to explore their options, with a lead plaintiff deadline of August 3, 2026.
WGS Deadline: WGS Investors with Losses in Excess of $100K Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors who purchased common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025, and May 4, 2026, of the August 3, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that GeneDx made misleading statements regarding the positive impact of its Fabric acquisition on the company's financials and operations, when in reality, significant problems existed that negatively impacted the business. Investors with losses exceeding $100,000 are encouraged to join the class action to seek compensation.
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) has reminded investors of GeneDx Holdings Corp. (NASDAQ: WGS) with substantial losses that they have until August 3, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that GeneDx and its executives failed to disclose material information, leading to a 49.2% stock decline after the company reported a drop in adjusted gross margin, missed revenue estimates, lowered full-year guidance, and disclosed a $31.2 million impairment loss related to its acquisition of Fabric Genomics. Investors who purchased shares between April 16, 2025, and May 4, 2026, are encouraged to contact KSF to discuss their legal rights.
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) has reminded investors of GeneDx Holdings Corp. (NASDAQ: WGS) with substantial losses that they have until August 3, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that GeneDx and its executives failed to disclose material information during the Class Period, leading to a significant drop in stock price after the company reported lower-than-expected financial results and an impairment loss related to its Fabric Genomics acquisition. Investors who purchased shares between April 16, 2025, and May 4, 2026, are encouraged to contact KSF for legal counsel.
GeneDx Holdings Corp. 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against GeneDx Holdings Corp. - WGS
Kahn Swick & Foti, LLC (KSF) is reminding investors in GeneDx Holdings Corp. (NasdaqGS: WGS) that they have until August 3, 2026, to apply for lead plaintiff in a securities class action lawsuit. The lawsuit alleges that GeneDx and its executives made false and misleading statements regarding the company's financial performance, including deteriorating adjusted gross margins and missed revenue estimates. These alleged misrepresentations led to a significant drop in GeneDx's stock price.
GENEDX HOLDINGS DEADLINE MONDAY AUGUST 3rd: Bragar Eagel & Squire, P.C. Urges GeneDx Holdings Corp. Investors to Contact the Firm Regarding Lead Plaintiff Deadline
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against GeneDx Holdings Corp. (NASDAQ:WGS) for alleged federal securities law violations. The lawsuit claims GeneDx made false and misleading statements about its business, leading to a significant drop in stock price after the company reported poor financial results and lowered revenue guidance. Investors who purchased WGS common stock between April 16, 2025, and May 4, 2026, have until August 3, 2026, to apply to be lead plaintiff.
HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GeneDx Holdings Corp. (NASDAQ: WGS) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 3, 2026 Lead Plaintiff Deadline
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS), urging investors with substantial losses to contact the firm. The lawsuit alleges that GeneDx and its executives misled investors regarding the benefits of acquiring Fabric Genomics, concealing integration problems that severely harmed the company's business. Following corrective disclosures on May 4, 2026, GeneDx's stock plummeted by 49.2%, resulting in significant shareholder value destruction.
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC is reminding investors that they have until August 3, 2026, to file lead plaintiff applications in a securities class action lawsuit against GeneDx Holdings Corp. The lawsuit alleges that GeneDx and its executives failed to disclose material information, leading to a 49.2% stock decline after the company reported disappointing Q1 2026 financial results and an impairment loss related to its acquisition of Fabric Genomics. Investors who purchased GeneDx shares between April 16, 2025, and May 4, 2026, are encouraged to contact KSF for more information.
MONDAY DEADLINE: GeneDx Holdings Corp. (WGS) Investors with
Robbins Geller Rudman & Dowd LLP announced a Monday, August 3, 2026 deadline for investors who purchased GeneDx Holdings Corp. (WGS) common stock between April 16, 2025, and May 4, 2026, to seek appointment as lead plaintiff in a class action lawsuit. The lawsuit alleges that GeneDx made false or misleading statements regarding the viability of its acquisition, Fabric Genomics, which led to a significant stock drop after the company revealed an impairment loss and reduced earnings projections. Investors who suffered substantial losses are encouraged to contact the firm to lead the class action.
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) has reminded investors of GeneDx Holdings Corp. that they have until August 3, 2026, to file lead plaintiff applications in a securities class action lawsuit. This action alleges that GeneDx and its executives made material misrepresentations regarding the company's performance, particularly concerning the Fabric Genomics acquisition, which led to a 49.2% stock decline after the company disclosed disappointing Q1 2026 financial results and lowered guidance. Investors who purchased shares between April 16, 2025, and May 4, 2026, and incurred substantial losses, are encouraged to contact KSF for legal guidance.
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 3, 2026 in GeneDx Holdings Corp. Lawsuit - WGS
SueWallSt is alerting investors of GeneDx Holdings Corp. (NASDAQ: WGS) about a pending securities class action lawsuit, with a lead plaintiff deadline of August 3, 2026. The lawsuit stems from the unraveling of GeneDx's acquisition of Fabric Genomics, which was initially touted as a growth catalyst but resulted in a $31.2 million impairment charge and a significant stock price drop. Shareholders who purchased WGS shares between April 16, 2025, and May 4, 2026, may be eligible to recover losses due to alleged misleading statements regarding the acquisition's potential.
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 3, 2026 in GeneDx Holdings Corp. Lawsuit - WGS
SueWallSt is alerting investors in GeneDx Holdings Corp. (WGS) about a pending securities class action lawsuit, with a lead plaintiff deadline of August 3, 2026. The lawsuit stems from the unraveling of WGS's acquisition of Fabric Genomics, which was initially promised as a growth catalyst but resulted in a $31.2 million impairment charge and a significant stock drop. The firm encourages shareholders who purchased WGS shares between April 16, 2025, and May 4, 2026, to contact them regarding potential recovery of losses.
MONDAY DEADLINE: GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - WGS
Robbins Geller Rudman & Dowd LLP announces a lead plaintiff deadline of Monday, August 3, 2026, for investors who purchased GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made false or misleading statements regarding the viability of Fabric Genomics, an AI-driven genomic interpretation firm it acquired, leading to a significant stock drop. Investors with substantial losses have the opportunity to seek appointment as lead plaintiff in the class action.
Class Action Lawsuit Filed Against GeneDx Holdings Corp. (WGS) - Recover Losses - Contact Levi & Korsinsky Before August 3, 2026
A class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ:WGS) by Levi & Korsinsky, LLP, on behalf of investors who purchased securities between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx Holdings Corp. made false and misleading statements regarding the viability and financial benefits of its Fabric acquisition, leading to artificially inflated stock prices. Investors who suffered losses are encouraged to contact Levi & Korsinsky to explore potential recovery under federal securities laws before August 3, 2026.
Levi & Korsinsky Reminds GeneDx Holdings Corp. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 3, 2026 - WGS
Levi & Korsinsky, LLP has issued a reminder to investors in GeneDx Holdings Corp. (NASDAQ: WGS) about a pending securities class action lawsuit. The lawsuit alleges that GeneDx management misled investors about deteriorating reimbursement rates and margin compression between April 16, 2025, and May 4, 2026. Investors who suffered losses have until August 3, 2026, to apply for lead plaintiff appointment.
WGS DEADLINE ALERT: GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit- August 3, 2026 Deadline
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GeneDx Holdings Corp. (WGS), alerting investors with substantial losses to an August 3, 2026 deadline to lead the class action. The lawsuit alleges that GeneDx misled investors about the benefits of its Fabric Genomics acquisition, concealing significant integration problems, which led to a substantial drop in share prices after corrective disclosures on May 4, 2026. Investors who purchased WGS common stock between April 16, 2025, and May 4, 2026, and suffered losses are encouraged to contact the firm.
WGS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026
Faruqi & Faruqi, LLP is reminding investors of the August 3, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS). The lawsuit alleges that GeneDx and its executives made misleading statements regarding the importance of Fabric Genomics, projected margins, and average reimbursement rates, which led to a significant drop in share price after the Q1 2026 financial results were announced. Investors who purchased GeneDx securities between April 16, 2025, and May 4, 2026, and suffered losses are encouraged to contact the law firm.
Levi & Korsinsky Reminds GeneDx Holdings Corp. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 3, 2026 - WGS
Levi & Korsinsky, LLP is alerting investors of GeneDx Holdings Corp. (NASDAQ: WGS) about a pending securities class action lawsuit. The lawsuit alleges that GeneDx concealed deteriorating reimbursement rates and margin compression, leading to a significant drop in share value. Investors who purchased WGS stock between April 16, 2025, and May 4, 2026, and suffered losses may be eligible to join, with a lead plaintiff deadline of August 3, 2026.
Portnoy Law Firm Announces Class Action on Behalf of GeneDX Holdings, Corp. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of GeneDX Holdings, Corp. (NASDAQ: WGS) investors who purchased securities between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDX and its executives made misleading statements regarding the importance of Fabric Genomics, its reimbursement rates, and its financial prospects. This action follows a significant drop in GeneDX's share price after the company missed Q1 financial results and cut its 2026 guidance.
BlackRock (NYSE: BLK) discloses 5.5% beneficial ownership in GeneDx (WGS)
BlackRock, Inc. has filed a Schedule 13G disclosing a 5.5% beneficial ownership in GeneDx Holdings Corp. (WGS). The filing indicates BlackRock owns 1,622,518 shares of Class A stock, with sole voting power over 1,588,670 shares and sole dispositive power over all 1,622,518 shares. No single client of BlackRock holds more than five percent of GeneDx's outstanding common shares.
WGS 6-DAY DEADLINE ALERT: GeneDx Holdings Corp. (NASDAQ: WGS) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 3, 2026 Lead Plaintiff Deadline
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS), urging investors with substantial losses to contact the firm before the August 3, 2026, lead plaintiff deadline. The lawsuit alleges GeneDx misled investors about the benefits and integration of its Fabric Genomics acquisition, concealing significant problems that led to a substantial drop in stock value after corrective disclosures. Investors who purchased WGS stock between April 16, 2025, and May 4, 2026, and suffered losses are encouraged to participate.
Portnoy Law Firm Announces Class Action on Behalf of GeneDX Holdings, Corp. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in GeneDX Holdings, Corp. (NASDAQ: WGS). The lawsuit alleges that GeneDX made false and misleading statements to investors between April 16, 2025, and May 4, 2026, regarding its business, including the importance of Fabric Genomics, its reimbursement rates, and gross margins. This announcement follows a significant share price drop after GeneDX missed Q1 financial targets and cut its 2026 guidance.
WGS Shareholders Have Opportunity to Lead GeneDx Holdings Corp. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Bronstein, Gewirtz & Grossman, LLC announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ:WGS) for alleged violations of federal securities laws. The lawsuit covers investors who purchased GeneDx securities between April 16, 2025, and May 4, 2026, claiming the company made false and misleading statements regarding its business, operations, and prospects, specifically concerning Fabric Genomics, margins, and reimbursement rates. Investors who suffered losses have until August 3, 2026, to request to be appointed as lead plaintiff.
Portnoy Law Firm Announces Class Action on Behalf of GeneDX Holdings, Corp. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors of GeneDX Holdings, Corp. (NASDAQ: WGS). The lawsuit alleges that GeneDX made false and misleading statements regarding the importance of Fabric Genomics, its margins, and average reimbursement rates, leading to a significant drop in share price. Investors who purchased securities between April 16, 2025, and May 4, 2026, have until August 3, 2026, to file as a lead plaintiff.
GeneDx Holdings Corp. Class A Revenue Breakdown – BX:WGS
This article provides an overview of GeneDx Holdings Corp. Class A (BX:WGS) financial information available on TradingView, focusing on its revenue breakdown and segments. It highlights that market data is provided by ICE Data Services and FactSet, with SEC filings from Quartr. The content mainly navigates through various financial and community features offered by TradingView related to the company.
MONDAY DEADLINE: GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead GeneDx Class Action Lawsuit - WGS
Investors in GeneDx Holdings Corp. (NASDAQ: WGS) who suffered losses between April 16, 2025, and May 4, 2026, have until August 3, 2026, to seek appointment as lead plaintiff in a class action lawsuit. The lawsuit alleges that GeneDx made misleading statements regarding the viability of its acquisition, Fabric Genomics, leading to a significant stock drop. Robbins Geller Rudman & Dowd LLP is representing the investors.
WGS 9-DAY DEADLINE ALERT: GeneDx Holdings Corp. (NASDAQ:
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS), urging investors with significant losses to come forward. The lawsuit alleges that GeneDx and its executives made false and misleading statements about the benefits of acquiring Fabric Genomics, concealing integration problems that led to missed revenue estimates, lowered guidance, and a $31.2 million impairment charge, causing a 49.2% stock plummet. The lead plaintiff deadline is August 3, 2026.
GENEDX HOLDINGS DEADLINE AUGUST 3rd: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against GeneDx Holdings Corp. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced a class action lawsuit filed against GeneDx Holdings Corp. (NASDAQ:WGS) on behalf of investors who purchased common stock between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx and its executives made false and misleading statements regarding the company's business, particularly concerning Fabric Genomics, reimbursement rates, and gross margins. Investors are encouraged to contact the law firm by the August 3, 2026 deadline to apply for lead plaintiff in the case.
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) has announced a securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS). Investors who purchased shares between April 16, 2025, and May 4, 2026, have until August 3, 2026, to file lead plaintiff applications. The lawsuit alleges that GeneDx failed to disclose material information, leading to a 49.2% stock decline after announcing lower-than-expected Q1 2026 financial results and an impairment loss related to its Fabric Genomics acquisition.
GeneDx Holdings Corp. (WGS) Investors: August 3, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP has announced a securities fraud class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS). The lawsuit, filed on behalf of investors who purchased WGS common stock between April 16, 2025, and May 4, 2026, alleges that GeneDx made materially false and misleading statements regarding the viability of its acquisition of Fabric Genomics. Investors have until August 3, 2026, to file for lead plaintiff status.
GeneDx Holdings Corp. (NASDAQ: WGS) Investors Who Suffered Losses May Be Eligible to Participate in Securities Class Action
Robbins LLP has filed a securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of investors who purchased shares between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx misled investors about the financial benefits of its acquisition of Fabric Genomics. This claim follows a significant decline in GeneDx's stock price after the company reported missed revenue estimates, lowered guidance, and a substantial impairment loss related to Fabric Genomics.
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against GeneDx Holdings Corp. (NASDAQ:WGS) and its officers, alleging violations of federal securities laws. The lawsuit claims that GeneDx made materially false and/or misleading statements regarding its business, operations, and prospects between April 16, 2025, and May 4, 2026, specifically concerning the importance of Fabric Genomics, potential margin issues, and reimbursement rates. Investors who suffered losses are encouraged to contact the firm to potentially serve as lead plaintiff before the August 3, 2026 deadline.
Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers. The lawsuit, filed on behalf of investors who purchased or acquired GeneDx securities between April 18, 2023, and May 4, 2026, alleges that the company made materially false and misleading statements and failed to disclose adverse facts regarding its business, operations, and prospects. Investors who suffered losses are encouraged to contact the firm by August 3, 2026, to request appointment as lead plaintiff.
Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm
A class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain officers, alleging violations of federal securities laws for investors who purchased securities between April 16, 2025, and May 4, 2026. The complaint claims that GeneDx made materially false or misleading statements regarding the importance of Fabric Genomics, negative impacts on margins, and non-durable reimbursement rates. Investors have until August 3, 2026, to request to be appointed as lead plaintiff in this case.
WGS 10-DAY DEADLINE ALERT: GeneDx Holdings Corp. (NASDAQ:
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS), urging investors with significant losses to come forward by the August 3, 2026, lead plaintiff deadline. The lawsuit alleges GeneDx misled investors about the benefits of its Fabric Genomics acquisition, concealing integration problems that led to a substantial impairment charge and a 49.2% stock plummet after its Q1 2026 financial results revealed missed estimates and lowered guidance. The firm is investigating alleged misrepresentations concerning the Fabric Genomics integration and its promised AI-driven efficiencies.
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) has initiated a securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS), urging investors with significant losses to file lead plaintiff applications by August 3, 2026. The lawsuit alleges that GeneDx and its executives made material misrepresentations during the Class Period (April 16, 2025, to May 4, 2026), leading to a 49.2% stock price drop after the company reported a decline in gross margin, missed revenue estimates, lowered guidance, and incurred a substantial impairment loss on its Fabric Genomics acquisition. Investors are encouraged to contact KSF to discuss their legal rights.
WGS 10-DAY DEADLINE ALERT: GeneDx Holdings Corp. (NASDAQ:
Hagens Berman Sobol Shapiro LLP is alerting investors of GeneDx Holdings Corp. (NASDAQ: WGS) about a securities fraud class action lawsuit. The lawsuit alleges that GeneDx misled investors regarding the benefits of its acquisition of Fabric Genomics, concealing integration problems that led to a significant impairment charge and a 49.2% stock drop. Investors who suffered losses between April 16, 2025, and May 4, 2026, have until August 3, 2026, to file as a lead plaintiff.
Class Action Alert: Levi & Korsinsky Reminds GeneDx Holdings Corp. (WGS) Investors of August 3, 2026 Deadline
Levi & Korsinsky, LLP has filed a securities class action lawsuit against GeneDx Holdings Corp. (WGS) on behalf of investors who purchased securities between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx Holdings Corp. made false and misleading statements about the viability and financial benefits of its Fabric acquisition. Investors who suffered losses are encouraged to learn about their rights to seek a recovery, with a deadline to participate set for August 3, 2026.
WGS UPCOMING DEADLINE : The Gross Law Firm Alerts GeneDx Holdings Corp. Stockholders of Securities Class Action - Contact the Firm
The Gross Law Firm has issued a notice to shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) regarding a securities class action lawsuit. The lawsuit alleges that the company made false and misleading statements about the Fabric acquisition, leading to artificially inflated stock prices during the class period of April 16, 2025, to May 4, 2026. Shareholders who purchased WGS shares during this time are encouraged to contact the firm before the lead plaintiff deadline of August 3, 2026.
WGS 10-DAY DEADLINE ALERT: GeneDx Holdings Corp. (NASDAQ:WGS) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 3, 2026 Lead Plaintiff Deadline
Hagens Berman Sobol Shapiro LLP is alerting investors of GeneDx Holdings Corp. (NASDAQ: WGS) about a securities fraud class action lawsuit, urging those with substantial losses to contact the firm before the August 3, 2026 lead plaintiff deadline. The lawsuit alleges that GeneDx misled investors by misrepresenting the strategic and financial benefits of its Fabric Genomics acquisition, concealing significant integration problems that led to a dramatic stock price plummet after corrective disclosures. Investors who purchased WGS common stock between April 16, 2025, and May 4, 2026, and suffered losses are encouraged to seek lead plaintiff status.
WGS UPCOMING DEADLINE : The Gross Law Firm Alerts GeneDx Holdings Corp. Stockholders of Securities Class Action - Contact the Firm
The Gross Law Firm has issued a notice to shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) regarding a securities class action lawsuit. The lawsuit alleges that the company made false or misleading statements concerning the viability and financial impact of its Fabric acquisition. Shareholders who purchased WGS shares between April 16, 2025, and May 4, 2026, are encouraged to contact the firm, with an August 3, 2026, deadline to seek lead plaintiff appointment.
GeneDx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against GeneDx Holdings Corp. - WGS
ClaimsFiler is reminding investors who suffered losses exceeding $100,000 in GeneDx Holdings Corp. (NasdaqGS: WGS) to file as lead plaintiff in a securities class action lawsuit by August 3, 2026. The lawsuit alleges that GeneDx and its executives failed to disclose material information during the Class Period, specifically regarding a significant drop in adjusted gross margin, missed revenue estimates, lowered full-year guidance, and a $31.2 million impairment loss related to the acquisition of Fabric Genomics. This news led to a 49.2% decrease in GeneDx share price, and affected investors are encouraged to seek legal counsel.
WGS DEADLINE ALERT: GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit- August 3, 2026 Deadline
Hagens Berman is actively investigating a securities class action lawsuit against GeneDx Holdings (NASDAQ: WGS) and its executives. The lawsuit alleges that investors were misled about the Fabric Genomics acquisition and its synergy potential, leading to a 49% stock collapse after a disastrous Q1 2026 earnings report and a $31.2 million impairment charge. GeneDx investors who suffered significant losses are urged to contact the firm before the August 3, 2026 deadline.
